Section 3
The PROTECT project Olaf Klungel, PharmD, PhD Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences,
September, 2005 HIMSS Interoperability Showcase New Directions in Life Sciences Theater Presentation Supporting Physician Reporting of Adverse Reactions.
Improving Spontaneous Reporting: A new business model Incorporating postmarket medical product safety data collection into the clinical practice workflow.
Advanced Therapy Regulation Hearing, Brussels May 11, 2006 Dr.Andreas Reimann CEO, Mukoviszidose e.V. (German Cystic Fibrosis Association) Vice-Chairman,
1 WHO Programme for International Drug Monitoring : ensuring the safety of medicines Dr Mary Couper & Dr Shanthi Pal Quality Assurance and Safety: Medicines.
Introduction to post marketing drug safety surveillance fda 2-11-14
Updates on the BioSense Program Redesign: 2011 Public Health Preparedness Summit
Novel Approaches in Public Health Surveillance
ASTER results at 2009 DIA
POST MARKETING SURVILLANCE
Adverse Event Analysis
